Of note, cucurbitacin B treatment also increases SESN3 at both mRNA and protein levels in epidermal growth factor receptor (EGFR)-mutant lung cancer cells, and this upregulation significantly contributes to the anti-proliferative and apoptotic effect of cucurbitacin B in EGFR-mutant lung cancer cells, providing a mechanistic rationale for its attractive potential therapeutic use in non-small cell lung carcinoma (NSCLC), especially given the challenging management of therapeutic resistance typical of these tumors [82]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.